Published in the final year of Era I, the UN Economic Bulletin’s retrospective on American healthcare traces an arc that mirrors the broader American collapse documented by Issa & Issa (2047): the system didn’t get fixed — the conditions that made it expensive simply stopped existing.
The Pre-Collapse Architecture
For most of the 20th and early 21st centuries, American healthcare cost was an international anomaly: a wealthy nation spending a larger share of its economy on medical care than any peer while producing worse population-level outcomes. Every attempted domestic reform through the 2010s and 2020s adjusted the edges without touching the structure — a small handful of insurers, a small handful of pharmaceutical manufacturers, and hospital consolidation that had, by the 2030s, left most metropolitan areas served by two or three dominant systems rather than a genuine market.
The Unwinding
The mechanism was not policy. It was decline. Three structural changes unfolded in sequence:
Insurance (2040s). As federal capacity contracted, the regulatory and lobbying infrastructure protecting the insurance-pharmaceutical-hospital consolidation lost sustained federal attention. State governments, operating with increasing de facto autonomy, began experimenting. Several states moved to public-option or single-payer models not from ideological victory but because insurers withdrew from destabilized regional markets, leaving states to backstop coverage or watch their populations go uninsured at politically untenable scale.
Pharmaceuticals (2050s). Generic drug manufacturing diversified sharply as new capacity came online across South and Southeast Asia, built to serve markets the collapsing American regulatory apparatus could no longer effectively gatekeep. American purchasers — increasingly state health authorities rather than a fragmented private insurance market — sourced directly from this expanded international base rather than through the domestic distribution chains that had maintained pricing power for decades. By the 2060s, multiple states operated de facto public pharmaceutical procurement systems that would have been legally unthinkable forty years earlier.
Hospitals (2070s). Population and capital flight hit hardest in the metropolitan markets where consolidation had been most extreme. Several dominant regional hospital systems entered financial distress, opening room for new entrants — including direct investment from state public health authorities acquiring distressed hospital assets rather than watching them close.
The Result
By the 2080s, several American states reported per-capita healthcare expenditure below the pre-collapse national average for the first time in over a century. The Bulletin is careful to note the outcome was neither efficient nor equitable by normal standards — the resulting patchwork varied wildly by state — but it was measurably cheaper. The most expensive features of the American system — concentrated insurer market power, unified national pharmaceutical pricing, extreme regional hospital consolidation — had depended on a level of coordinated federal capacity that the broader collapse removed, “without any single reform ever being passed to remove it deliberately.”
The retrospective’s closing assessment: the durability of a national system’s most expensive features can turn out to be more contingent on political capacity than on anything structural, and their removal does not necessarily produce the collapse in access that maintaining them was supposedly protecting against.